StockDrifts LogoStockDrifts

Invenire Partners 13F Portfolio

Portfolio Manager
Invenire Partners, Lp
Performance
0% (N/A)
AUM (13F)
$65.27K
# of Holdings
26
Performance Rank
N/A
Allocation (Top 20)
N/A
Latest filing
Q3 2022

Invenire Partners, Lp Holdings Map

Top 24 Invenire Partners, Lp Holdings

Top 10 holdings

StockCompany% Port.SharesValueActivityOwnershipAvg. CostDate
HROW
Harrow Health Inc
8.38%453.8K$5.5Mnew2022-Q3: 453.8K sharesโ€”2022-09-30
DHX
DHI Group Inc
7.93%964.2K$5.2Mnew2022-Q3: 964.2K sharesโ€”2022-09-30
TTI
Tetra Technologies Inc
6.5%1.18M$4.3Mnew2022-Q3: 1.18M sharesโ€”2022-09-30
APYX
Apyx Medical Corp
6.49%945.7K$4.2Mnew2022-Q3: 945.7K sharesโ€”2022-09-30
INFU
InfuSystem Holdings Inc
4.99%466.7K$3.3Mnew2022-Q3: 466.7K sharesโ€”2022-09-30
AREN
Arena Group Holdings Inc
4.83%241.4K$3.2Mnew2022-Q3: 241.4K sharesโ€”2022-09-30
CTLP
Cantaloupe Inc
4.73%888.3K$3.1Mnew2022-Q3: 888.3K sharesโ€”2022-09-30
PAR
PAR Technology Corp
4.54%100.6K$3.0Mnew2022-Q3: 100.6K sharesโ€”2022-09-30
EGIO
Edgio Inc
4.46%1.05M$2.9Mnew2022-Q3: 1.05M sharesโ€”2022-09-30
MCS
Marcus Corp
4.4%207.1K$2.9Mnew2022-Q3: 207.1K sharesโ€”2022-09-30

About Invenire Partners, Lpโ€™s portfolio

Invenire Partners, Lp reports $65.27K in US-listed equity holdings across 26 positions in its most recent 13F filing. Its largest disclosed positions are HROW (8.4%), DHX (7.9%) and TTI (6.5%). Figures reflect the Q3 2022 filing.

Portfolio concentration

Portfolio concentration
HROW โ€” 8.4% ($5.48M)DHX โ€” 7.9% ($5.19M)TTI โ€” 6.5% ($4.25M)APYX โ€” 6.5% ($4.25M)INFU โ€” 5.0% ($3.26M)AREN โ€” 4.8% ($3.16M)CTLP โ€” 4.7% ($3.09M)PAR โ€” 4.5% ($2.97M)EGIO โ€” 4.5% ($2.92M)MCS โ€” 4.4% ($2.88M)Other โ€” 42.7% ($27.89M)
57%in top 10
  • HROW8.4%
  • DHX7.9%
  • TTI6.5%
  • APYX6.5%
  • INFU5.0%
  • AREN4.8%
  • CTLP4.7%
  • PAR4.5%
  • EGIO4.5%
  • MCS4.4%
  • Other42.7%

Unlock alerts, watchlists & AI chat

Sign up free to track Invenire Partners, Lp, compare funds side by side, and get alerts the moment positions change.

Source filings

Holdings on this page are parsed from Invenire Partners, Lpโ€™s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1726823). View Invenire Partners, Lpโ€™s 13F filings on SEC

More 13F analyses

View all